Akso Health Group/$AHG
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Akso Health Group
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
- Ticker
- $AHG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 12
- Headquarters
- Qingdao, China
- Website
- www.ahgtop.com
AHG Metrics
BasicAdvanced
$1.2B
-
-$0.03
-1.00
-
Price and volume
Market cap
$1.2B
Beta
-1
52-week high
$2.50
52-week low
$0.68
Average daily volume
24K
Financial strength
Current ratio
21.766
Quick ratio
0.167
Long term debt to equity
0
Total debt to equity
0.013
Profitability
EBITDA (TTM)
-1.628
Gross margin (TTM)
-0.08%
Net profit margin (TTM)
-134.99%
Operating margin (TTM)
-28.92%
Effective tax rate (TTM)
9.60%
Revenue per employee (TTM)
$1,150,000
Management effectiveness
Return on assets (TTM)
-1.24%
Return on equity (TTM)
-9.85%
Valuation
Price to revenue (TTM)
70.537
Price to book
6.39
Price to tangible book (TTM)
6.39
Price to free cash flow (TTM)
-5.177
Free cash flow yield (TTM)
-19.32%
Free cash flow per share (TTM)
-0.261
Growth
Revenue change (TTM)
-6.40%
Earnings per share change (TTM)
-93.75%
3-year revenue growth (CAGR)
1.62%
10-year revenue growth (CAGR)
1.52%
3-year earnings per share growth (CAGR)
-28.58%
10-year earnings per share growth (CAGR)
-18.77%
Bulls say / Bears say
Akso’s FY2026 net loss narrowed to US$18.67 million from US$134.98 million a year earlier, and its loss from continuing operations per share also fell. If it can sustain this improvement, it would ease the pressure to fund ongoing losses. (MarketScreener)
Akso has described plans to enter US cancer therapy and radiation oncology, including a large proposed network of centres. If it can secure funding and execute, this could create a new growth platform beyond its small existing business. (Tickeron)
The company’s brain-computer interface work spans neural sensing, AI-based decoding and interface engineering, offering a potential technology growth option. It remains very early: human trials have not begun and the programme has no revenue. (Kalkine)
FY2026 revenue fell to US$13.83 million from US$14.78 million, while the remaining marketing-promotion business reportedly earned only a 0.10% gross margin. That leaves little evidence of a profitable operating base. (MarketScreener, EveryTicker)
The auditor raised substantial doubt about Akso’s ability to continue as a going concern. Cash in bank was just US$0.2 million at 31 March 2026, down from US$176.2 million a year earlier. (MarketScreener, StockTitan)
Investors own an offshore holding company, while operations are largely in China; the annual filing warns that regulatory intervention or uncertainty around the structure could disrupt operations or the listing. This adds risks beyond the company’s already fragile finances. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
AHG Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.